The University of Chicago Header Logo

Matthew Koshy

Concepts (288)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
25
2022
1177
4.890
Why?
Lung Neoplasms
33
2022
2474
4.440
Why?
Chemoradiotherapy
19
2022
337
3.480
Why?
Radiosurgery
15
2025
352
3.310
Why?
Carcinoma, Squamous Cell
14
2021
1107
2.780
Why?
Hodgkin Disease
6
2016
144
2.010
Why?
Neoplasm Staging
36
2022
2087
1.970
Why?
Oropharyngeal Neoplasms
7
2022
152
1.950
Why?
Neoadjuvant Therapy
12
2017
477
1.880
Why?
Adenocarcinoma
9
2020
1215
1.820
Why?
Radiotherapy, Intensity-Modulated
8
2019
200
1.550
Why?
Databases, Factual
15
2022
1102
1.470
Why?
Brain Neoplasms
10
2025
845
1.330
Why?
Carcinoma, Large Cell
4
2021
38
1.210
Why?
Chemoradiotherapy, Adjuvant
6
2020
40
1.200
Why?
Middle Aged
68
2026
29642
1.180
Why?
Aged
58
2026
21986
1.130
Why?
Radiotherapy Planning, Computer-Assisted
8
2019
215
1.130
Why?
Neoplasm Recurrence, Local
8
2026
1538
1.110
Why?
Male
78
2026
47475
1.100
Why?
Glioblastoma
5
2025
301
1.090
Why?
Papillomavirus Infections
5
2022
311
1.060
Why?
Chemotherapy, Adjuvant
5
2019
527
1.030
Why?
Female
77
2026
51997
1.020
Why?
Radiotherapy Dosage
13
2019
478
0.950
Why?
Aged, 80 and over
29
2025
7461
0.940
Why?
SEER Program
17
2025
252
0.930
Why?
Small Cell Lung Carcinoma
3
2022
144
0.900
Why?
Survival Analysis
14
2019
1530
0.870
Why?
Humans
100
2026
98799
0.860
Why?
Meningioma
4
2026
70
0.860
Why?
Survival Rate
17
2025
2057
0.860
Why?
Meningeal Neoplasms
4
2026
79
0.860
Why?
United States
32
2025
8387
0.860
Why?
Adult
52
2026
29698
0.850
Why?
Kaplan-Meier Estimate
13
2020
909
0.840
Why?
Combined Modality Therapy
14
2019
1754
0.830
Why?
Neoplasm, Residual
3
2016
205
0.820
Why?
Proportional Hazards Models
14
2020
925
0.820
Why?
Follow-Up Studies
20
2026
4049
0.810
Why?
Registries
6
2025
1133
0.810
Why?
Young Adult
28
2025
7598
0.800
Why?
Palliative Care
3
2018
291
0.800
Why?
Early Detection of Cancer
4
2021
563
0.790
Why?
Transplantation Conditioning
7
2025
389
0.730
Why?
Esophageal Neoplasms
3
2016
355
0.720
Why?
Neoplasms, Second Primary
2
2015
244
0.650
Why?
Retrospective Studies
29
2026
11104
0.610
Why?
Extremities
2
2013
173
0.610
Why?
Nasopharyngeal Neoplasms
2
2017
48
0.610
Why?
Healthcare Disparities
5
2021
558
0.600
Why?
Radiotherapy, Conformal
3
2017
88
0.600
Why?
Lymph Nodes
4
2020
563
0.600
Why?
Sarcoma
2
2013
222
0.590
Why?
Adolescent
20
2025
10168
0.590
Why?
Radiotherapy, Adjuvant
10
2026
325
0.590
Why?
Prognosis
15
2026
4139
0.580
Why?
Multivariate Analysis
9
2017
1007
0.570
Why?
Cohort Studies
14
2026
3242
0.570
Why?
Carcinoma
5
2022
442
0.520
Why?
Treatment Outcome
19
2022
9806
0.520
Why?
Stomach Neoplasms
3
2017
321
0.520
Why?
Tongue Neoplasms
1
2017
51
0.520
Why?
Hospitals, Low-Volume
1
2017
28
0.510
Why?
Health Services Accessibility
2
2021
548
0.510
Why?
Cytoreduction Surgical Procedures
3
2025
105
0.500
Why?
Mass Screening
2
2021
753
0.490
Why?
Hospitals, High-Volume
1
2017
53
0.490
Why?
Hematopoietic Stem Cell Transplantation
5
2025
979
0.470
Why?
Tomography, X-Ray Computed
7
2021
2680
0.470
Why?
Mouth Neoplasms
2
2020
223
0.460
Why?
Esophagectomy
3
2016
94
0.440
Why?
Whole-Body Irradiation
5
2025
70
0.440
Why?
Thoracic Neoplasms
1
2015
63
0.440
Why?
Induction Chemotherapy
1
2016
152
0.430
Why?
Practice Patterns, Physicians'
2
2020
669
0.430
Why?
Mortality
2
2016
160
0.420
Why?
Propensity Score
8
2020
218
0.420
Why?
Insurance, Health
5
2016
192
0.420
Why?
Antineoplastic Combined Chemotherapy Protocols
6
2025
2666
0.410
Why?
Tumor Burden
6
2020
330
0.400
Why?
Insurance Coverage
4
2017
159
0.400
Why?
Preoperative Care
2
2017
420
0.390
Why?
Central Nervous System
1
2014
144
0.380
Why?
Radiation Injuries
1
2014
160
0.370
Why?
Pneumonectomy
1
2015
222
0.370
Why?
Organs at Risk
5
2019
55
0.370
Why?
Immunotherapy
1
2019
831
0.360
Why?
Angiogenesis Inhibitors
1
2014
281
0.350
Why?
Disease-Free Survival
5
2020
1196
0.330
Why?
Ependymoma
1
2011
30
0.330
Why?
Antibodies, Monoclonal, Humanized
2
2015
1105
0.330
Why?
Logistic Models
4
2020
1276
0.300
Why?
Lymphatic Metastasis
5
2020
519
0.300
Why?
Breast Neoplasms
6
2015
3303
0.300
Why?
Socioeconomic Factors
3
2017
675
0.300
Why?
Brachytherapy
3
2015
139
0.290
Why?
Papillomaviridae
4
2022
184
0.290
Why?
Myeloablative Agonists
3
2025
38
0.290
Why?
Busulfan
3
2025
41
0.290
Why?
Radiation Oncology
4
2018
130
0.280
Why?
Soft Tissue Neoplasms
1
2009
127
0.280
Why?
Gallbladder Neoplasms
1
2008
24
0.270
Why?
Lymphoma, B-Cell, Marginal Zone
1
2008
23
0.270
Why?
Prostatic Neoplasms
5
2020
1846
0.270
Why?
Lymph Node Excision
3
2020
238
0.270
Why?
Clinical Clerkship
3
2014
117
0.260
Why?
Head and Neck Neoplasms
3
2022
1091
0.260
Why?
Vidarabine
2
2025
107
0.250
Why?
Dacarbazine
2
2017
104
0.240
Why?
Neoplasm Grading
6
2026
425
0.240
Why?
Peripheral Blood Stem Cell Transplantation
2
2018
67
0.230
Why?
Salivary Gland Neoplasms
2
2021
88
0.230
Why?
Ki-67 Antigen
1
2026
70
0.230
Why?
Vipoma
1
2025
4
0.230
Why?
Comorbidity
3
2020
1037
0.230
Why?
Shock
1
2025
49
0.220
Why?
Transplantation, Homologous
2
2025
1029
0.220
Why?
Regression Analysis
3
2017
578
0.220
Why?
Neoplasms, Radiation-Induced
1
2005
96
0.220
Why?
Diarrhea
1
2025
180
0.210
Why?
Anemia, Sickle Cell
2
2018
158
0.210
Why?
Osteosarcoma
1
2005
156
0.210
Why?
Cisplatin
2
2016
578
0.210
Why?
Patient Selection
2
2020
725
0.200
Why?
Child, Preschool
4
2015
4053
0.200
Why?
Child
5
2015
7771
0.200
Why?
Prevalence
3
2020
1396
0.190
Why?
Radiotherapy
3
2016
325
0.190
Why?
Otorhinolaryngologic Surgical Procedures
2
2020
18
0.190
Why?
Academic Medical Centers
2
2016
416
0.190
Why?
Analysis of Variance
3
2017
890
0.190
Why?
Postoperative Care
2
2017
239
0.190
Why?
Bone Neoplasms
2
2021
316
0.190
Why?
Career Choice
2
2014
167
0.180
Why?
Neurosurgical Procedures
1
2026
404
0.170
Why?
Delivery of Health Care
1
2026
483
0.170
Why?
Neoplasm Invasiveness
3
2017
583
0.170
Why?
Intracranial Arteriovenous Malformations
1
2022
147
0.170
Why?
Mastectomy
3
2015
277
0.170
Why?
Carcinoma, Neuroendocrine
1
2021
48
0.160
Why?
Odontogenic Tumors
1
2020
11
0.160
Why?
Carcinoma, Adenoid Cystic
1
2021
46
0.160
Why?
Magnetic Resonance Angiography
1
2022
284
0.150
Why?
Time-to-Treatment
1
2021
163
0.150
Why?
Neoplasms
4
2017
3382
0.150
Why?
Time Factors
3
2026
5586
0.150
Why?
Antineoplastic Agents, Alkylating
2
2017
136
0.140
Why?
Pancreatic Neoplasms
1
2025
782
0.140
Why?
Curriculum
2
2014
643
0.140
Why?
Liver Neoplasms
1
2025
840
0.140
Why?
Chemotherapy, Cancer, Regional Perfusion
1
2018
18
0.140
Why?
Risk Factors
4
2020
6295
0.140
Why?
Transplantation, Haploidentical
1
2018
29
0.140
Why?
Glossectomy
1
2017
4
0.130
Why?
Hyperthermia, Induced
1
2018
77
0.130
Why?
Risk Assessment
3
2024
2604
0.130
Why?
Oral Surgical Procedures
1
2017
20
0.130
Why?
Reward
1
2020
228
0.130
Why?
Minority Groups
1
2018
166
0.120
Why?
Thymoma
1
2017
31
0.120
Why?
Endosonography
1
2017
103
0.120
Why?
Functional Laterality
1
2017
199
0.120
Why?
Guideline Adherence
2
2015
251
0.120
Why?
Organ Transplantation
1
2020
307
0.120
Why?
Thymus Neoplasms
1
2017
48
0.120
Why?
Peritoneal Neoplasms
1
2018
196
0.120
Why?
Bronchi
1
2017
229
0.120
Why?
Practice Guidelines as Topic
2
2021
1116
0.120
Why?
Margins of Excision
1
2016
50
0.120
Why?
Prostate
1
2020
434
0.120
Why?
Cancer Care Facilities
1
2016
43
0.120
Why?
Magnetic Resonance Imaging
2
2019
3622
0.110
Why?
Taxoids
1
2016
127
0.110
Why?
Private Sector
1
2015
25
0.110
Why?
Head
1
2016
135
0.110
Why?
Carboplatin
1
2016
331
0.110
Why?
Positron Emission Tomography Computed Tomography
1
2016
108
0.110
Why?
Immunosuppressive Agents
1
2020
1021
0.110
Why?
Relative Biological Effectiveness
1
2015
14
0.110
Why?
Odds Ratio
1
2017
728
0.110
Why?
Social Class
1
2016
156
0.110
Why?
Carcinoma, Ductal, Breast
2
2015
167
0.110
Why?
Epidemiologic Methods
1
2015
60
0.110
Why?
Confidence Intervals
2
2015
221
0.110
Why?
Mesothelioma
1
2018
342
0.110
Why?
Dose-Response Relationship, Radiation
1
2015
193
0.110
Why?
Population Surveillance
1
2016
218
0.110
Why?
Needs Assessment
2
2014
174
0.100
Why?
Disease Management
1
2017
378
0.100
Why?
Community Health Services
1
2015
83
0.100
Why?
Fluorouracil
1
2016
543
0.100
Why?
Unrelated Donors
1
2014
50
0.100
Why?
Program Evaluation
2
2014
349
0.100
Why?
Graft Survival
1
2018
999
0.100
Why?
Students, Medical
3
2014
450
0.100
Why?
Necrosis
1
2014
225
0.100
Why?
Phantoms, Imaging
1
2016
493
0.100
Why?
Surveys and Questionnaires
1
2021
3058
0.090
Why?
Multiple Myeloma
1
2017
372
0.090
Why?
Sex Factors
2
2021
1144
0.090
Why?
Bone Marrow
2
2025
419
0.090
Why?
Bevacizumab
1
2014
255
0.090
Why?
Endometrial Neoplasms
1
2015
243
0.090
Why?
Uterine Cervical Neoplasms
1
2015
326
0.090
Why?
Clinical Trials, Phase III as Topic
1
2011
172
0.080
Why?
Length of Stay
1
2015
889
0.080
Why?
Clinical Competence
2
2014
873
0.080
Why?
Patient Readmission
1
2015
441
0.080
Why?
Predictive Value of Tests
1
2015
1792
0.080
Why?
Hematologic Neoplasms
1
2014
384
0.080
Why?
Lymphatic Irradiation
1
2010
7
0.080
Why?
Thoracic Wall
1
2010
26
0.080
Why?
Remission Induction
1
2011
764
0.070
Why?
Postoperative Complications
1
2020
2719
0.070
Why?
Recurrence
2
2025
1274
0.070
Why?
Gastrectomy
2
2017
75
0.060
Why?
Endoscopy, Gastrointestinal
1
2008
171
0.060
Why?
Quality of Life
1
2015
1904
0.060
Why?
World Health Organization
1
2026
125
0.060
Why?
Retinoblastoma
1
2005
30
0.060
Why?
Rhabdomyosarcoma
1
2005
44
0.060
Why?
Sarcoma, Ewing
1
2005
42
0.060
Why?
Biopsy
1
2008
1226
0.050
Why?
Diagnosis, Differential
1
2008
1571
0.050
Why?
Allografts
2
2015
221
0.050
Why?
Graft vs Host Disease
1
2025
382
0.050
Why?
Age Factors
2
2020
1976
0.050
Why?
Cetuximab
1
2022
119
0.040
Why?
Medicaid
2
2015
287
0.040
Why?
Mastectomy, Segmental
2
2012
119
0.040
Why?
Eligibility Determination
1
2021
42
0.040
Why?
Medical History Taking
1
2021
81
0.040
Why?
Hypopharyngeal Neoplasms
1
2020
15
0.040
Why?
Cerebrovascular Circulation
1
2022
243
0.040
Why?
Chicago
2
2016
1520
0.040
Why?
Cigarette Smoking
1
2021
59
0.040
Why?
Laryngeal Neoplasms
1
2020
89
0.040
Why?
Cell Proliferation
1
2026
1801
0.040
Why?
Infant, Newborn
1
2005
2556
0.040
Why?
Lung
2
2016
1409
0.030
Why?
Infant
1
2005
3368
0.030
Why?
Cranial Irradiation
1
2018
42
0.030
Why?
Clinical Decision-Making
1
2020
306
0.030
Why?
Retreatment
1
2017
106
0.030
Why?
Melphalan
1
2017
98
0.030
Why?
Body Mass Index
1
2021
869
0.030
Why?
Prospective Studies
2
2017
4837
0.030
Why?
Maximum Tolerated Dose
1
2017
265
0.030
Why?
Consensus
1
2018
308
0.030
Why?
Machine Learning
1
2020
413
0.030
Why?
Medicare
1
2020
528
0.030
Why?
Transplantation, Autologous
1
2017
398
0.030
Why?
Smoking
1
2020
676
0.030
Why?
Workflow
1
2016
88
0.030
Why?
Alemtuzumab
1
2015
91
0.030
Why?
Antineoplastic Agents, Hormonal
1
2016
161
0.030
Why?
Esophagus
1
2016
113
0.030
Why?
Medically Uninsured
1
2015
71
0.030
Why?
Androgen Antagonists
1
2016
157
0.030
Why?
Professional Practice
1
2015
44
0.030
Why?
Patient Protection and Affordable Care Act
1
2015
69
0.030
Why?
Actuarial Analysis
1
2014
60
0.030
Why?
Spinal Cord
1
2016
244
0.030
Why?
Sensitivity and Specificity
1
2018
1946
0.030
Why?
Boston
1
2014
42
0.030
Why?
Consumer Behavior
1
2014
35
0.020
Why?
Randomized Controlled Trials as Topic
1
2018
995
0.020
Why?
Drug Resistance, Neoplasm
1
2017
671
0.020
Why?
Hospitals, Teaching
1
2014
117
0.020
Why?
Self Concept
1
2014
141
0.020
Why?
Program Development
1
2014
141
0.020
Why?
Poverty
1
2015
216
0.020
Why?
Heart
1
2016
527
0.020
Why?
Neoplasm Metastasis
1
2017
1102
0.020
Why?
Marital Status
1
2012
44
0.020
Why?
Data Collection
1
2014
376
0.020
Why?
Image Processing, Computer-Assisted
1
2019
1305
0.020
Why?
Matched-Pair Analysis
1
2012
41
0.020
Why?
Health Expenditures
1
2013
118
0.020
Why?
Receptors, Progesterone
1
2012
208
0.020
Why?
Internet
1
2014
359
0.020
Why?
Societies, Medical
1
2015
687
0.020
Why?
Algorithms
1
2019
2005
0.020
Why?
Receptors, Estrogen
1
2012
431
0.020
Why?
Robotic Surgical Procedures
1
2015
425
0.020
Why?
Positron-Emission Tomography
1
2009
354
0.020
Why?
Antineoplastic Agents
1
2017
2386
0.010
Why?
Koshy's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (288)
Explore
_
Co-Authors (31)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_